Indolent CD4+ CAR T-Cell Lymphoma after Cilta-cel CAR T-Cell Therapy
Menée auprès de 724 patients atteints d'un cancer traité par immunothérapie à base de lymphocytes CAR-T, cette étude analyse le risque de lymphome à cellules T lié au traitement
Indolent CD4+ cytotoxic chimeric antigen receptor (CAR) T-cell lymphoma involving the small intestine was diagnosed in a patient who had previously received ciltacabtagene autoleucel (cilta-cel) CAR T-cell therapy for treatment of myeloma. Targeted messenger RNA sequencing revealed the presence of CAR gene product in tumor cells. Whole-genome sequencing of samples of tumor and peripheral blood identified a single lentiviral insertion site within the second intron of the SSU72 gene. In addition, numerous genetic alterations that may have contributed to malignant transformation were identified in the tumor sample. (Funded by MedStar Georgetown University Hospital.) A patient in whom diarrhea had developed 4 months after BCMA-directed CAR T-cell therapy for myeloma was found to have an indolent CD4+ lymphoma of the small intestine containing the CAR gene product.
New England Journal of Medicine , résumé, 2023